EU patent court invalidates Enanta patent in Pfizer Paxlovid dispute
PFE•The EU's Unified Patent Court ruled Enanta Pharmaceuticals' patent invalid on October 29, 2026, finding its infringement suit against Pfizer over Paxlovid in 18 participating EU member states unfounded.
1. Court ruling
The EU's Unified Patent Court ruled Enanta Pharmaceuticals' patent invalid on October 29, 2026, finding its infringement suit against Pfizer over Paxlovid in 18 participating EU member states unfounded. Pfizer had sought revocation of the patent, and a hearing on both claims took place on September 29, 2026.
